Big pharma: Eli Lilly stock erases 6 years of dividends after failed drug trial
What investors had hoped would build into yet another 2.68 percent dividend yield for pharmaceutical behemoth Eli Lilly has turned into a massive financial letdown after trials of solanezum [...]